Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

By H. Gelderblom, J. Verweij, K. Nooter, A. Sparreboom. European Journal of Cancer, 2001

1,599 citations recorded by the source corpus.

Subfields: Dermatology, Oncology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/b1f1c575022cba40537cb5d8bfcdb91ce2328bf4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. N. Desai
2. Colin W. Pouton
3. D. Shin
4. Shuming Nie
5. D. McClements
6. Jiajia Rao

In Pharmacology

1. W. Charman
2. Colin W. Pouton
3. Christopher J. H. Porter
4. S. Charman
5. H. Williams
6. R. Shanker
7. Natalie L. Trevaskis

Citations in the corpus

• Challenges in Development of Nanoparticle-Based Therapeutics (2012, background): “conventional formulation of the hydrophobic drug paclitaxel (Bristol-Myers Squibb Co), contains a high concentration of Cremophor-EL® (BASF, Ludwigshafen, Germany), a solvent associated with significant toxicities including potentially lethal hypersensitivity, anaphylactic reactions, and prolonged p”
• Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer (2009, neutral): “which may be associated with demyelination and axonal degeneration.(25,26,29) CrEL can also cause neutropenia.”
• Role of nanotechnology in targeted drug delivery and imaging: a concise review. (2005, methodology): “Finally, nanocarriers composed of biocompatible materials [13-16] are investigated as safe alternatives to existing vehicles, such as CremophorR EL (BASF, Mount Olive, NJ), that may cause hypersensitivity reactions and peripheral neuropathy [17,18].”
• Nanotechnology applications in cancer. (2007, background): “The formulation is very effective in circumventing side effects of the highly toxic Chremophor EL, which include hypersensitivity reactions, nephrotoxicity, and neurotoxicity (126, 129).”
• Block copolymer micelles: preparation, characterization and application in drug delivery. (2005, background): “TaxolR, the commercial form of paclitaxel, is formulated in micelles of CrmEL, a low-molecular weight surfactant known for its side effects (acute hypersensitivity and severe neurotoxicity) [99].”
• Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. (2012, background): “However both strategies can lead to low bioavailability, sensitization reactions, and other secondary side effects [34, 35].”
• SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. (2003, neutral): “% Peripheral blood blasts (range) 14 (1-75)”
• Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery (2006, methodology): “To enhance drug solubility, paclitaxel is formulated with the micelle-forming vehicle cremophor EL (polyxyethylated castor oil) and ethanol (42).”
• Albumin-bound paclitaxel: a next-generation taxane (2006, background): “CrEL leaches plasticisers from standard di(2-ethylhexyl)phthalate (DEHP) infusion sets and causes hypersensitivity reactions, which can be severe, and sometimes fatal [7-12].”